COVID-19: Our series of regulatory legislation trackers for the Life Sciences & Healthcare industry - UAE

Written By

melissa murray Module
Melissa Murray

Partner
United Arab Emirates

I am the head of the Intellectual Property Group for the Middle East offices and a partner in the International Commercial Group. I've practised in the UAE since 2006 and I'm ranked in IP Stars, Chambers & Partners, Legal 500 and Who's Who Legal for my commercial and intellectual property experience.

surabhi singhi Module
Surabhi Singhi

Partner
United Arab Emirates

I'm a partner in our Corporate Group, based in the UAE, where I work as a lead counsel in M&A transactions. I also specialise in provision of employment law solutions to our clients.

Partner, Melissa Murray and Senior Associate, Surabhi Singhi provided content for the United Arab Emirates.

COVID-19 presents an unprecedented challenge to the global life sciences industry. Members of Bird & Bird's International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships with regulatory bodies, have worked together to provide an update in the form of a Q&A for each of the countries we are located. This update aims to provide guidance on the responses of EU, Asia-Pac and UAE regulators in the areas of clinical trials, medical devices, market access, public procurement and compulsory licensing.

Read more >

 

Latest insights

More Insights
featured image

EPO Upholds, UPC Revokes: A Tale of Diverging Views on PCSK9 Antibody Patent

2 minutes Jul 02 2025

Read More
featured image

The possible end of the Green Claims Directive: Is it all Greenwashing now?

4 minutes Jun 26 2025

Read More
Ferris wheel

Horizon Scanning 2025/2026

Jun 25 2025

Read More